#Italy #Milan #MGI Tech #DNBSEQ #DNBelab

MGI Tech Presents Multi-Omics Advancements at ESHG 2025 in Milan

At the European Society of Human Genetics (ESHG) 2025 conference held in Milan, MGI Tech Co., Ltd. (MGI) showcased its state-of-the-art multi-omics technologies, geared to revolutionize research in life sciences. Attendees were particularly drawn to MGI's innovative multi-omics solutions designed to enhance precision and efficiency in genetic research.

Cutting-Edge Innovations Unveiled

One of the highlights presented at Booth #310 was the DNBSEQ-T1+, a mid-throughput sequencer, along with the new DNBelab C-YellowR 16, a single-cell library preparation workstation that was debuted to the global audience. The DNBelab C-YellowR 16 allows for the simultaneous processing of up to 16 single-cell samples while significantly reducing hands-on time by as much as 90%.

The automation in the DNBelab C-YellowR 16 ensures a seamless workflow, transitioning from cell and nucleus suspension input directly to DNA nanoballs (DNBs) ready for sequencing. This platform incorporates several integrated functional modules, allowing for a fully automated experience without needing user intervention. The independent pipetting module facilitates the plate transfer and pipetting processes, while the on-board modules handle cell sorting, PCR, and purification, ensuring rigorous quality control.

Unprecedented Workflow Efficiency

The YellowR 16 raised the bar with its unattended workflow capabilities, handling everything from cell sorting to library preparation and quality control, thereby addressing common challenges faced in manual single-cell operations such as complexity and low throughput. MGI underpinned the versatility of its platform by addressing cross-research challenges, including scenarios that involve limited RNA inputs. The new library preparation solution allows for full-length transcriptome profiling from as little as 10 picograms of RNA, which is crucial for researchers working with limited sample quantities.

Dr. Christian Zimmerman, VP of Sales for Europe and Africa at MGI, expressed excitement about their participation in ESHG, emphasizing the remarkable momentum surrounding integrated multi-omics workflows. He stated, "Our platforms, like Stereo-seq and the DNBelab C-YellowR 16, are generating immense interest and feedback from researchers and laboratories across Europe."

Engaging Demonstrations and Symposiums

The exhibits included vibrant live demonstrations that won over attendees, showcasing innovative workflows and strategies to maximize efficiency in genomic research. MGI's versatile sequencing platforms were on display, ranging from compact benchtop designs to ultra-high-throughput systems, including the DNBSEQ-T1+, first unveiled at the AGBT 2025 conference.

While at ESHG, MGI also hosted a Corporate Satellite Symposium where leading experts discussed real-world applications of the DNBSEQ™ platform. Notably, Prof. Jānis Kloviņš from the Latvian Biomedical Research and Study Centre elaborated on his research efforts to construct a national genomic infrastructure as part of the European 1+ Million Genomes Initiative. Utilizing the DNBSEQ-T7 for whole genome sequencing, his team is creating a comprehensive population reference for both rare disease diagnostics and polygenic risk scoring.

Commitment to Advancing Genomics in Europe

Dr. Eirini Papadopoulou from Genekor Medical S.A. in Greece discussed NGS-based multigene panels that are redefining precision oncology, while Dr. Xin Jin from BGI-Research shared insights from the China Kadoorie Biobank, which utilized MGI technologies to sequence over 500,000 genomes in just six months – a testament to MGI’s capability to support large-scale, population-wide genomic research.

Dr. Yong Hou, the General Manager for Europe and Africa at MGI, reinforced the company’s dedication to advancing genomics within Europe through significant contributions to landmark initiatives. He remarked, "Our focus remains on enhancing accessibility to genomics across Europe, fostering projects that contribute to personalized medicine."

This year not only marks the unveiling of transformative technologies but also the 10th anniversary of MGI's DNBSEQ™ technology. Trusted in over 100 countries globally, MGI is committed to driving innovations in genomics that hold potential for worldwide health impact.